Postpone the SSC Decision For Two Years

There are several arguments against the Superconducting Supercollider that come from outside high-energy physics. High-energy physics, an exciting pioneer field in science, suffers from Big Science syndrome: it requires massive efforts in human and material resources to further the acquisition of knowledge. Meanwhile, areas systemic research show great promise with only moderate expenditure of resources. Huge potential breakthroughs in the principles of accelerator building (such as the superc

Written byMichael Moravcsik
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

There are also arguments internal to high-energy physics. In the last 50 years a series of ever-costlier accelerators have been built, each demanded by the theoretical high-energy physicists as indispensable for finding the solution to the central "strong interaction" problem. The new accelerators caused the older ones to be shut down for lack of funds even though the latter could still have been used to do interesting research. Thus, each machine was very much underutilized.

Yet today, after a sequence of unsuccessful theoretical attempts, we still do not understand strong interactions. Hardly 10 percent of the data accumulated by past accelerators can be explained (even to an accuracy of 10 percent) by existing theories. Even worse, the latest theories claim that most of these data were taken in the wrong range of parameters, and, hence, new data from new accelerators are needed to make progress.

On the basis of this ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies